Pfizer asks FDA to clear Covid pill for high-risk patients


Pfizer asks FDA to clear Covid pill for high-risk patients

Paxlovid is second oral antiviral to undergo FDA review as drugmaker moves to widen access to oral treatment

Riley Griffin

Pfizer has asked US regulators for emergency-use authorisation of its Covid-19 pill that could play a critical role in further protecting high-risk patients from the disease’s worst effects. 

The drug, Paxlovid, blocks a crucial enzyme that’s key to the growth of the coronavirus and would be the first of its sort if cleared, Pfizer said in a statement. Unlike most other Covid treatments, it could be prescribed for home use.

Doctors have been calling for more and better Covid therapies, and Pfizer’s is the second oral Covid antiviral to go before the Food and Drug Administration. Last month, Merck & Co and its partner Ridgeback Biotherapeutics submitted data from molnupiravir to the agency, after a study showed it lowered the risk of serious illness or death by half in patients with mild to moderate disease. ..

This article is reserved for Sunday Times Daily subscribers.
A subscription gives you full digital access to all Sunday Times Daily content.

Sunday Times Daily

Already subscribed? Simply sign in below.

Questions or problems?
Email or call 0860 52 52 00.

Next Article

Harsh climate: why Shell is divorcing the Netherlands after 114 years

By Laura Hurst, Diederik Baazil and Fred Pals
7 min read